At #ACMGMtg23, we presented a poster on “Prospective Longitudinal Validation of a Breast Cancer Risk Prediction Model in a Cohort of 130,058 Individuals," which was awarded Top Abstract honors! Learn more about MyRisk with RiskScore®: https://t.co/scpBEr2Iom @TheACMG
I wanted to put the following invitation on everyone's radar. We will be joined by Bita Nehoray and Tinamarie Bauman as well as a legal expert. Bring your questions! https://t.co/9UTetzJfHQ
I wanted to put the following invitation on everyone's radar. We will be joined by Bita Nehoray and Tinamarie Bauman as well as a legal expert. Bring your questions! https://t.co/9UTetzJfHQ
@LGtheCGC@CorpConventions@myriadgenetics It is an SNV and borders on the definition of a SNP. The mean allele frequency though in the population at around 0.5% is lower than a standard SNP definition. However the association with breast cancer as shown is far lower than a standard CHEK2 PV. Glad to have it part of PRS!
Attention #NSGC22 first timers: join Myriad Genetics and @GeneticCouns for the First Time Attendee Reception from 6:00-7:00 p.m. CT. Location: room 101. #GeneChat
Live at #NSGC22 on Friday at 12:15 p.m. CT, don't miss this fireside chat with Myriad Genetics president and CEO, Paul J. Diaz. More information here: https://t.co/sUrkGHXcIK
If you are attending #NSGC22, visit the Myriad Genetics booth 307 and learn how genetic insights can help to improve the health and well-being of patients. https://t.co/FqTBZCzyKv #GeneChat@GeneticCouns